JPWO2005033307A1 - 新規のリフォールディング方法およびその方法によって得られたタンパク質 - Google Patents

新規のリフォールディング方法およびその方法によって得られたタンパク質 Download PDF

Info

Publication number
JPWO2005033307A1
JPWO2005033307A1 JP2005514502A JP2005514502A JPWO2005033307A1 JP WO2005033307 A1 JPWO2005033307 A1 JP WO2005033307A1 JP 2005514502 A JP2005514502 A JP 2005514502A JP 2005514502 A JP2005514502 A JP 2005514502A JP WO2005033307 A1 JPWO2005033307 A1 JP WO2005033307A1
Authority
JP
Japan
Prior art keywords
protein
receptor
refolding
ligand
refolded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005514502A
Other languages
English (en)
Japanese (ja)
Inventor
出 大木
出 大木
真一 楯
真一 楯
Original Assignee
技術研究組合 生物分子工学研究所
技術研究組合 生物分子工学研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 技術研究組合 生物分子工学研究所, 技術研究組合 生物分子工学研究所 filed Critical 技術研究組合 生物分子工学研究所
Publication of JPWO2005033307A1 publication Critical patent/JPWO2005033307A1/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP2005514502A 2003-09-30 2004-09-30 新規のリフォールディング方法およびその方法によって得られたタンパク質 Withdrawn JPWO2005033307A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003342645 2003-09-30
JP2003342645 2003-09-30
PCT/JP2004/014801 WO2005033307A1 (fr) 2003-09-30 2004-09-30 Nouvelle methode de repli et proteine ainsi obtenue

Publications (1)

Publication Number Publication Date
JPWO2005033307A1 true JPWO2005033307A1 (ja) 2006-12-14

Family

ID=34419268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005514502A Withdrawn JPWO2005033307A1 (ja) 2003-09-30 2004-09-30 新規のリフォールディング方法およびその方法によって得られたタンパク質

Country Status (2)

Country Link
JP (1) JPWO2005033307A1 (fr)
WO (1) WO2005033307A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1324779B1 (fr) 2000-09-29 2011-07-20 Schering Corporation Interleukine 10 pegylee
DE102004041639A1 (de) * 2004-08-27 2006-03-02 Bioceuticals Arzneimittel Ag Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies
EP2360170A3 (fr) * 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Réduction et dérivatisation de protéines obtenues par génie génétique comprenant au moins une cystéine non native
JP5093711B2 (ja) * 2006-03-23 2012-12-12 独立行政法人農業・食品産業技術総合研究機構 Ａｇｅを認識する分子
AU2007314501B2 (en) 2006-09-28 2013-05-23 Merck Sharp & Dohme Corp. Use of pegylated IL-10 to treat cancer
WO2013136180A2 (fr) * 2012-03-12 2013-09-19 Scaratech Medical Ab Protéines chimériques pour le traitement de maladies
US9850316B2 (en) 2013-02-15 2017-12-26 National University Corporation Kyoto Institute Of Technology Method for refolding antibody, process for producing refolded antibody, refolded antibody, and uses thereof
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
WO2015070060A1 (fr) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Méthodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3237441A4 (fr) * 2014-12-23 2018-06-06 Armo Biosciences, Inc. Procédés d'amélioration du rendement dans la production de protéines recombinées
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
EP3302547A1 (fr) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19631326A1 (de) * 1996-08-02 1998-02-05 Basf Ag Verfahren zum Wirkstoff-Screening unter Einsatz der Rasterkraft-Mikroskopie
JPH10191989A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd ベータセルリン類の製造方法
JPH10234386A (ja) * 1996-12-26 1998-09-08 Takeda Chem Ind Ltd 成長ホルモン類の製造方法
CN1217194C (zh) * 2001-01-04 2005-08-31 上海数康生物科技有限公司 蛋白芯片及其制备方法和使用方法

Also Published As

Publication number Publication date
WO2005033307A1 (fr) 2005-04-14

Similar Documents

Publication Publication Date Title
Di Mattia et al. FFAT motif phosphorylation controls formation and lipid transfer function of inter‐organelle contacts
JPWO2005033307A1 (ja) 新規のリフォールディング方法およびその方法によって得られたタンパク質
Hejjaoui et al. Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125
US7449300B2 (en) Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
JPWO2006073195A1 (ja) 糖尿病の予知・診断方法および糖尿病予知・診断用キット
US20060111287A1 (en) Acetylated protein
Rintala-Dempsey et al. Insights into S100 target specificity examined by a new interaction between S100A11 and annexin A2
WO2010011952A2 (fr) Peptides très puissants pour lutter contre le cancer et les maladies neurodégénératives
JP3127996B2 (ja) 合成老化細胞抗原
JP2011168505A (ja) ポリカーボネートおよび／またはポリメタクリル酸メチル親和性ペプチド、およびその利用
JP5093711B2 (ja) Ａｇｅを認識する分子
Wu et al. Effects of glycosylation and D-amino acid substitution on the antitumor and antibacterial activities of bee venom peptide HYL
US20130316958A1 (en) Highly potent peptides to control cancer and neurodegenerative diseases
CN111138521A (zh) 源自于afp抗原的短肽
JP2004125785A (ja) ビオチン化タンパク質を用いる受容体チップおよびその作製方法
JP2004125785A6 (ja) ビオチン化タンパク質を用いる受容体チップおよびその作製方法
WO2003055908A2 (fr) Sequences de proteines et de nucleotides bag3 a utiliser dans la recherche, le diagnostic et le traitement de maladies impliquant la mort cellulaire, et a des fins de modulation de survie et/ou de mort cellulaire
WO2006107078A1 (fr) Procede destine a evaluer l’efficacite du traitement par interferon et kit d’evaluation de celle-ci
JP2003248001A (ja) リガンドとの分子間相互作用を有するタンパク質のスクリーニング方法
JP5688829B2 (ja) 示差的な糖尿病の予知・診断方法および糖尿病予知・診断用キット
US20090087445A1 (en) Method for the Redox Potential-Dependent Detection of Target Molecules by Interacting Polypeptides
JP4911575B2 (ja) Ａｇｅを認識するリフォールディングされた分子
JP2009103718A (ja) ビオチン化タンパク質を用いる受容体チップおよびその作製方法
US6743630B2 (en) Method of preparing a protein array based on biochemical protein-protein interaction
Han et al. Structural basis of a high-affinity antibody binding to glycoprotein region with consecutive glycosylation sites

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060927

A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20071204